<DOC>
	<DOC>NCT02106260</DOC>
	<brief_summary>This phase I/IIa study has an open-label, First-in-Human (FIH), single center design to assess the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of multiple doses of topically applied CLS003 in healthy subjects with cutaneous warts.</brief_summary>
	<brief_title>First-in-Human Study of CLS003 ICVT in Subjects With Cutaneous Warts</brief_title>
	<detailed_description />
	<mesh_term>Warts</mesh_term>
	<criteria>Healthy subjects (male, nonpregnant female), 18 to 65 years of age, inclusive. Body mass index (BMI) between 18 and 30kg/m2, inclusive Fitzpatrick skin type IIIIIIIV At least 4 cutaneous warts on the hands, separated by at least 1cm of skin For women, a positive pregnancy test and/or nursing at screening A positive test for drugs of abuse at screening History of alcohol or illicit drug abuse Positive test results for Hepatitis B, Hepatitis C or HIV Have used salicylic acid or any other overthecounter wartremoving product in the treatment area within 30 days prior to enrollment Have received cryotherapy in the treatment area within 60 days prior to enrollment Have required systemic intake of immunosuppressive or immunomodulatory medication (including oral or parenteral corticosteroids) with 30 days prior to enrollment or during the course of the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>safety</keyword>
	<keyword>pharmacokinetics (PK)</keyword>
	<keyword>pharmacodynamics (PD)</keyword>
	<keyword>CLS003</keyword>
</DOC>